antibodi
essenti
molecul
tool
basic
research
diagnost
therapi
first
polyclon
antibodi
produc
serum
hors
mileston
antibodi
gener
develop
hybridoma
technolog
allow
product
monoclon
antibodi
hybridoma
technolog
drawback
like
limit
number
candid
possibl
instabl
aneuploid
cell
line
inabl
provid
antibodi
highli
conserv
antigen
limit
applic
gener
human
antibodi
hybridoma
technolog
thu
essenti
allow
isol
murin
antibodi
broad
detect
rang
appli
diagnost
research
use
howev
therapeut
applic
limit
repeat
administr
murin
antibodi
caus
human
antimous
antibodi
reaction
hama
reduc
antibodi
halflif
sever
side
effect
includ
anaphylact
shock
strategi
circumv
problem
antibodi
human
use
transgen
anim
origin
antibodi
gene
repertoir
replac
human
gene
repertoir
strategi
human
hybridoma
technolog
result
human
antibodi
technolog
subject
murin
hybridoma
technolog
limit
immun
system
technolog
circumv
limit
immun
system
antibodi
phage
display
technolog
complet
independ
immun
system
vitro
select
process
display
method
commonli
use
today
base
work
georg
p
smith
filament
phage
infect
e
coli
select
process
call
pan
refer
gold
digger
tool
phage
display
technolog
develop
antibodi
three
place
parallel
heidelberg
germani
cambridg
uk
la
jolla
usa
antibodi
phage
display
describ
detail
tomszak
et
al
select
recombin
human
antibodi
book
brief
antibodi
fragment
display
surfac
phage
correspond
antibodi
gene
packag
phage
particl
mainli
use
phagemid
common
antibodi
format
use
antibodi
phage
display
singl
chain
fragment
variabl
scfv
fragment
antigen
bind
fab
antibodi
format
use
phage
display
singl
chain
fab
scfab
human
vh
domain
dab
variabl
domain
camel
heavi
chain
vhh
immunoglobulin
shark
ignar
specif
antibodi
phage
select
antibodi
gene
librari
pan
desir
target
final
monoclon
antibodi
phage
monoclon
solubl
antibodi
identifi
eg
elisa
antibodi
fragment
gene
reclon
antibodi
format
eg
scfvfc
igg
phage
display
librari
built
immun
nonimmun
lymphocyt
donor
synthet
repertoir
librari
use
naiv
igm
repertoir
donor
correspond
primari
immun
respons
synthet
antibodi
sequenc
summar
singlepot
univers
librari
univers
librari
design
isol
antibodi
fragment
everi
possibl
antigen
least
theori
librari
type
use
gener
antibodi
virus
toxin
immun
librari
construct
patient
immun
human
anim
also
immun
librari
human
antibodi
select
virus
toxin
detail
antibodi
gene
librari
given
chapter
select
recombin
human
antibodi
tomszak
et
al
date
antibodi
antibodi
conjug
approv
ema
andor
fda
statu
summer
http
wwwimgtorgmabdbindex
antibodi
develop
approv
therapeut
antibodi
cancer
autoimmun
diseas
mechan
therapeut
antibodi
manifold
includ
neutral
substanc
eg
toxin
cytokin
like
tumor
necrosi
factor
tnf
alpha
block
receptor
like
epiderm
growth
factor
receptor
egfr
bind
cell
modul
host
immun
system
combin
effect
date
two
recombin
antibodi
approv
treatment
virus
toxin
raxibacumab
human
antibodi
anthrax
treatment
deriv
phage
display
librari
cambridg
antibodi
technolog
medimmun
antibodi
palivizumab
treatment
respiratori
syncyti
viru
rsv
bronchiol
classic
humanis
antibodi
overview
recombin
antibodi
deriv
phage
display
virus
toxin
given
review
larg
panel
antibodi
variou
virus
gener
either
naiv
immun
librari
use
phage
display
technolog
pan
peptid
recombin
viral
protein
complet
viru
particl
led
identif
antibodi
direct
human
pathogen
virus
sin
nombr
viru
dengu
viru
influenza
viru
veev
noroviru
sar
coronaviru
hepat
c
naiv
antibodi
gene
librari
antibodi
select
immun
antibodi
gene
librari
target
eg
weev
hiv
sar
yellow
fever
viru
influenza
viru
even
semisynthet
librari
use
gener
antibodi
specif
influenza
viru
librari
origin
differ
speci
success
employ
isol
viru
specif
antibodi
past
among
other
librari
construct
macaqu
mous
chimpanze
llama
human
origin
commonli
viru
specif
antibodi
isol
librari
scfv
format
fab
librari
vhh
librari
also
success
use
follow
paragraph
give
detail
exampl
antibodi
gener
use
phage
display
antibodi
engin
differ
viru
group
vaccinia
viru
prototyp
viru
genu
orthopoxviru
rel
larg
dna
viru
genom
kbp
genu
orthopoxviru
includ
variou
speci
monkeypox
viru
cowpox
viru
especi
variola
viru
caus
agent
smallpox
human
natur
occur
smallpox
erad
massiv
vaccin
program
begun
howev
vaccin
civilian
popul
conduct
nowaday
potenti
threat
intent
releas
renew
search
safe
effect
smallpox
vaccin
case
fatal
rate
among
unvaccin
subject
report
orthopoxvirus
highli
relat
assum
immun
one
poxviru
goe
along
immun
member
entir
viru
famili
use
immun
scfv
phage
display
librari
construct
vaccinia
viru
immun
patient
panel
human
vaccinia
specif
antibodi
select
plaquereduct
neutral
test
reveal
seven
antibodi
neutral
vaccinia
well
cowpox
viru
vitro
five
antibodi
addit
neutral
monkeypox
viru
antibodi
gener
fab
immun
librari
deriv
vaccinia
viru
immun
chimpanze
convert
chimer
chimpanzeehuman
igg
format
two
antibodi
display
high
affin
vaccinia
protein
kd
nm
antibodi
neutral
vitro
vaccinia
smallpox
viru
proof
protect
mice
challeng
vaccinia
viru
even
administ
day
challeng
model
proof
provid
significantli
greater
protect
previous
isol
rat
antibodi
vaccinia
use
model
final
confirm
protect
smallpox
possibl
ebola
viru
marburg
viru
two
filovirus
caus
sever
hemorrhag
fever
possess
high
mortal
human
addit
public
health
concern
associ
natur
outbreak
ebola
viru
might
potenti
agent
biolog
warfar
bioterror
human
antibodi
direct
ebola
viru
select
librari
origin
patient
recov
infect
ebola
viru
outbreak
kikwit
democrat
republ
congo
sever
antibodi
variou
viral
protein
nucleoprotein
envelop
glycoprotein
secret
envelop
glycoprotein
isol
studi
one
antibodi
specif
envelop
glycoprotein
neutral
vitro
fab
neutral
full
igg
neutral
followup
studi
show
effect
protect
vivo
guinea
pig
ebola
challeng
model
antibodi
administ
h
post
viral
challeng
interestingli
protect
macaqu
challeng
ebola
even
antibodi
given
twodos
treatment
first
dose
day
prior
viral
challeng
second
dose
day
post
challeng
murin
scfv
two
shark
ignar
v
immun
librari
gener
inactiv
zair
ebolaviru
yield
variou
antibodi
specif
viral
matrix
protein
viral
nucleoprotein
interestingli
work
repres
first
exampl
success
target
ignar
v
isol
shark
immun
respons
librari
dengu
viru
denv
member
flavivirida
famili
respons
least
million
symptomat
infect
year
develop
major
health
econom
burden
countri
worldwid
posit
strand
rna
viru
kb
genom
compromis
singl
open
read
frame
four
circul
serotyp
dengu
viru
show
approxim
sequenc
homolog
fab
monoclon
antibodi
dengu
type
viru
isol
chimpanze
immun
librari
two
fab
name
neutral
effici
titer
plagu
reduct
neutral
test
anoth
studi
select
human
scfv
antibodi
specif
dengu
viru
envelop
protein
pan
recombin
full
length
envelop
protein
domain
iii
denv
envelop
protein
essenti
molecul
virion
assembl
viru
entri
scfv
select
studi
shown
exhibit
inhibitori
effect
denv
infect
vitro
dengu
nonstructur
protein
essenti
viral
replic
host
immun
respons
modul
make
excel
target
dengueinhibit
antibodi
naiv
human
fabphag
librari
screen
specif
antibodi
fragment
use
variou
variant
dengu
viru
serotyp
antigen
pan
character
use
altern
dengu
serotyp
round
pan
strategi
result
identif
two
clone
crossreact
four
dengu
serotyp
anoth
studi
select
antibodi
use
phage
display
pan
dengu
viru
particl
directli
captur
supernat
infect
vero
cell
highli
serotyp
specif
antibodi
could
gener
total
nine
antibodi
seven
shown
specif
one
serotyp
one
select
clone
crossreact
dengu
wherea
anoth
clone
show
crossreact
serotyp
despit
select
sole
dengu
particl
interestingli
obtain
antibodi
recogn
sever
strain
distinct
genotyp
within
correspond
serotyp
pan
dengu
envelop
protein
identifi
antibodi
mousehuman
chimer
fab
librari
crossreact
neutral
cellbas
assay
convers
full
length
igg
besid
scfv
fab
also
variabl
domain
heavychain
antibodi
vhh
antibodi
select
use
phage
display
technolog
four
round
pan
recombin
denv
protein
posit
clone
select
affin
measur
reveal
kd
valu
best
vhh
antibodi
venezuelan
equin
enceph
viru
veev
alphaviru
togovirida
famili
caus
equin
epidem
also
caus
enceph
human
viru
classifi
categori
b
agent
center
diseas
control
prevent
cdc
much
research
done
gener
neutral
antibodi
antibodi
gener
immun
librari
human
donor
target
veev
envelop
glycoprotein
isol
fab
neutral
vitro
time
effect
subsequ
convert
full
igg
format
employ
gener
neutralizationescap
variant
veev
epitop
map
within
anoth
studi
immun
macaqu
librari
use
gener
humanlik
antibodi
one
antibodi
scfvfc
protect
mice
administ
h
post
viral
challeng
veev
trinidiad
strain
mice
surviv
lethal
viral
dose
howev
scfvfc
abl
neutral
trinidad
strain
veev
strain
vitro
show
neutral
mandatori
vivo
protect
antibodi
anoth
studi
describ
select
antibodi
human
naiv
scfv
gene
librari
use
complet
activ
veev
particl
antigen
specif
detect
veev
strain
select
antibodi
proven
remark
none
select
scfv
phage
clone
show
crossreact
alphaviru
speci
eastern
equin
enceph
viru
eeev
western
equin
enceph
viru
weev
antigen
complex
chikungunya
viru
chikv
make
ideal
tool
immunolog
detect
diagnosi
alphaviru
speci
two
differ
scfv
antibodi
librari
construct
weev
immun
macaqu
subclon
scfvfc
three
antibodi
librari
specif
bound
weev
elisa
littl
crossreact
alphavirus
found
neutral
vitro
studi
first
antibodi
weev
shown
neutral
vitro
develop
ngml
best
antibodi
neutral
weev
overview
recombin
antibodi
gener
phage
display
virus
given
tabl
sever
toxin
classifi
center
diseas
control
prevent
cdc
categori
b
agent
relev
diagnost
therapeut
easili
dissemin
result
high
moder
mortal
rate
antibodi
phage
display
present
power
tool
antibodi
select
allow
isol
neutral
antibodi
complet
activ
toxin
special
domain
differ
human
naiv
antibodi
gene
librari
high
divers
isol
highaffin
antibodi
specif
target
anim
immun
toxoid
nontox
subunit
select
toxin
domain
altern
human
materi
immun
patient
use
construct
immun
librari
follow
paragraph
give
detail
exampl
antibodi
gener
use
phage
display
antibodi
engin
differ
toxin
far
antibodi
phage
display
success
use
antibodi
select
panel
toxin
classifi
categori
agent
clostridium
botulinum
botul
bacillu
anthraci
anthrax
also
differ
categori
b
agent
staphylococc
enterotoxin
b
ricin
toxin
ricinu
communi
exampl
highrisk
microorgan
produc
toxic
substanc
known
highest
risk
potenti
use
bioweapon
gramposit
anaerob
sporeform
bacterium
clostridium
botulinum
clostridium
subspeci
secret
eight
differ
serotyp
botulinum
neurotoxin
bont
five
serotyp
b
e
rare
f
one
case
h
known
caus
human
botul
diseas
character
flaccid
muscl
paralysi
requir
intens
hospit
care
passiv
immun
especi
serotyp
recogn
toxic
substanc
known
valu
lethal
dose
ngkg
intraven
subcutan
rout
ngkg
pulmonari
rout
bont
compos
disulfid
bondlink
kda
light
chain
kda
heavi
chain
heavi
chain
contain
two
function
domain
hc
hn
respons
toxin
uptak
nerv
cell
receptormedi
endocytosi
transloc
light
chain
across
membran
neuron
cytosol
wherea
catalyt
domain
light
chain
respons
bont
toxic
current
approach
treatment
botul
includ
applic
human
antibotul
immunoglobulin
babi
botul
immun
globulin
babybig
equin
antitoxin
serum
human
serum
stock
babybig
limit
equin
antitoxin
may
caus
hypersensit
serum
sick
antibodi
phage
display
provid
technolog
gener
toxinneutr
antibodi
serotyp
instanc
macaqu
immun
librari
use
isol
neutral
scfv
nm
affin
light
chain
bonta
also
antibodi
heavi
chain
relev
serotyp
bont
therapeut
interest
phage
display
technolog
also
use
isol
singl
domain
antibodi
vhh
immun
llama
cocktail
seven
bont
toxoid
anoth
approach
gener
human
antibodi
gene
librari
induc
bontaspecif
immun
respons
vitro
immun
furthermor
antibodi
phage
display
use
gener
antibodi
clostridi
toxin
clostridium
tetani
clostridium
difficil
anthrax
anoth
seriou
infecti
diseas
caus
bacillu
anthraci
aerob
gramposit
sporeform
bacterium
found
soil
around
world
bacillu
anthraci
secret
two
toxin
lethal
toxin
lt
edema
toxin
et
toxin
compos
two
subunit
lt
consist
lethal
factor
lf
protect
antigen
pa
et
form
edema
factor
ef
pa
demonstr
lt
essenti
role
pathogenesi
anthrax
subunit
pa
basi
current
vaccin
induc
gener
neutral
antibodi
combin
antibiot
commerci
monoclon
antibodi
pa
raxibacumab
commonli
use
treatment
fda
approv
raxibacumab
treat
inhal
anthrax
due
secur
issu
use
antipa
antibodi
alon
question
sinc
pa
could
modifi
lose
recogn
epitop
retain
biolog
activ
altern
antipa
antibodi
antibodi
target
lf
isol
immun
librari
via
antibodi
phage
display
technolog
combin
antipa
antibodi
antilf
antibodi
could
lead
synergist
effect
improv
efficaci
therapi
exampl
bacteri
toxin
classifi
categori
b
agent
staphylococcu
enterotoxin
b
staphylococcu
aureu
bacteria
potenti
caus
agent
foodborn
ill
produc
type
staphylococc
enterotoxin
caus
symptom
food
poison
includ
abdomin
cramp
vomit
diarrhea
staphylococc
enterotoxin
b
seb
singl
polypeptid
kda
potent
toxin
secret
aureu
superantigen
stimul
cell
lead
overproduct
cytokin
caus
clinic
symptom
fever
hypertens
case
death
phage
display
use
gener
recombin
antibodi
murin
immun
librari
identifi
epitop
seb
specif
monoclon
antibodi
use
peptid
phage
librari
furthermor
human
monoclon
antibodi
seb
isol
synthet
human
antibodi
gene
librari
inhibit
seb
bind
mhcii
phage
display
technolog
also
use
isol
antibodi
ricin
ricin
kda
glycoprotein
castor
bean
plant
ricinu
communi
consist
two
distinct
subunit
rta
rtb
rtb
galactos
nacetylgalactosamin
specif
lectin
bind
specif
sugar
residu
cell
surfac
allow
intern
toxin
endocytosi
wherea
rta
rna
nglycosidas
activ
irrevers
inactiv
eukaryot
ribosom
result
inhibit
protein
synthesi
ricin
also
classifi
categori
b
agent
cdc
humanlik
antibodi
select
phage
display
macaqu
immun
rta
one
antibodi
picomolar
affin
neutral
biolog
activ
ricin
vitro
furthermor
neutral
antibodi
high
affin
select
llama
immun
librari
addit
differ
toxin
classifi
cdc
categori
b
agent
number
relev
toxin
almost
endless
addit
differ
anim
known
produc
high
potenti
toxin
contain
complex
composit
exampl
one
tityu
serrulatu
known
brazilian
yellow
scorpion
danger
scorpion
brazil
major
toxic
compon
venom
serrulatu
gamma
toxin
polypeptid
amino
acid
residu
neutral
antibodi
isol
human
librari
via
phage
display
protect
mice
procedur
use
bothrop
jararacussu
venom
pit
viper
speci
endem
south
america
use
human
antibodi
gene
librari
differ
antibodi
select
inhibit
phospholipas
activ
venom
vitro
reduc
myotox
vivo
toxin
also
produc
marin
organ
exampl
tetrodoxin
ttx
toxic
puffer
fish
scfv
select
human
naiv
antibodi
gene
librari
neutral
ttx
activ
overview
recombin
antibodi
gener
phage
display
toxin
given
tabl
antibodi
phage
display
allow
gener
antibodi
mainli
two
type
sourc
immun
naiv
librari
immun
librari
prefer
immun
anim
convalesc
patient
avail
offer
chanc
directli
isol
neutral
andor
protect
antibodi
immun
possibl
ethic
feasibl
naiv
antibodi
gene
librari
altern
approach
antibodi
gener
process
limit
immun
system
antibodi
phage
display
provid
panel
antibodi
use
diagnost
therapi
toxin
virus
